M. Fisher

Publications378
h-index60
Citations17,341
Highly Influential Citations371
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Saver
  • 7,127 Publications • 72,316 Citations
  • G. Albers
  • 758 Publications • 61,500 Citations
  • G. Donnan
  • 1,089 Publications • 60,543 Citations
  • A. Demchuk
  • 834 Publications • 54,506 Citations
  • Publications
  • Influence
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
TLDR
This updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of isChemic stroke or transient ischemic attack and to all clinicians who manage secondary prevention for these patients.
View on PubMed
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
TLDR
The updated STAIR preclinical recommendations reinforce the previous suggestions that reproducibly defining dose response and time windows with both histological and functional outcomes in multiple animal species with appropriate physiological monitoring is appropriate.
View on Wolters Kluwer
A call for transparent reporting to optimize the predictive value of preclinical research
TLDR
The main workshop recommendation is that at a minimum studies should report on sample-size estimation, whether and how animals were randomized, whether investigators were blind to the treatment, and the handling of data.
View on Nature
Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy: Results of the NeuroThera Effectiveness and Safety Trial–1 (NEST-1)
TLDR
The NEST-1 study indicates that infrared laser therapy has shown initial safety and effectiveness for the treatment of ischemic stroke in humans when initiated within 24 hours of stroke onset.
View on Wolters Kluwer
Normobaric Hyperoxia Delays Perfusion/Diffusion Mismatch Evolution, Reduces Infarct Volume, and Differentially Affects Neuronal Cell Death Pathways after Suture Middle Cerebral Artery Occlusion in…
TLDR
NBO significantly extended the time window for reperfusion, induced lasting neuroprotection in permanent ischemia, and although capable of reducing cell death in hypoperfused tissue it also induced cellDeath in otherwise unaffected areas, suggesting that NBO may represent a promising strategy for acute stroke treatment.
View on SAGE
Dilemmas in the management of atrial fibrillation in chronic kidney disease.
TLDR
An individualized stratification algorithm is presented based on relevant studies on the high risk for stroke and the conflicting data about oral anticoagulation in patients with chronic kidney disease.
View on PubMed
Future of neuroprotection for acute stroke: In the aftermath of the SAINT trials
TLDR
New suggestions to bridge the chasm between preclinical animal modeling and acute human stroke trials to potentially enhance the future assessment of novel neuroprotective drugs are discussed.
View on Wiley
Pulse Inhibition of Histone Deacetylases Induces Complete Resistance to Oxidative Death in Cortical Neurons without Toxicity and Reveals a Role for Cytoplasmic p21waf1/cip1 in Cell Cycle-Independent…
TLDR
It is demonstrated that pulse inhibition of HDACs in cortical neurons can induce neuroprotection without apparent toxicity, and that oxidative stress in this model induces neuronal cell death via cell cycle-independent pathways that can be inhibited by a cytosolic, noncanonical action of p21waf1/cip1.
View on Publisher
Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
TLDR
The results obtained allowed us to assess the importance of knowing the carrier and removal status of canine coronavirus, as a source of infection for other animals, not necessarily belonging to the same breeds.
View on Wolters Kluwer
Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials
TLDR
There is significant heterogeneity in the quality of animal testing for neuroprotective agents in stroke, and drugs in the post-SAINT era have not been subjected to more thorough preclinical evaluation.
View on Wolters Kluwer
...
...